Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 97
- Q2 2025, −6 vs. previous quarter
- 13F value
- $125.9M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding YMAB, Q2 2025
No superinvestor reported holding YMAB at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Y-mAbs Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2025 (view filing) | Mar 7 | 4 days | Rossi Michael JPRESIDENT & CEO | SSale | −3.92K | $5.20 | −$20.4K | −2.8%137.1K after | |
| Mar 11, 2025 (view filing) | Mar 7 | 4 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −10.8K | $5.23 | −$56.5K | −5.1%202.7K after | |
| Sep 17, 2024 (view filing) | Sep 13-16 | 4 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −95.0K | $13.31 | −$1.26M | −58.4%67.7K after | 2 lots |
| Aug 30, 2024 (view filing) | Aug 28 | 2 days | Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICER | SSale | −50.0K | $15.37 | −$768.5K | −58.4%35.6K after | |
| Aug 27, 2024 (view filing) | Aug 26 | 1 day | Wilms JorisSVP & CHIEF OPERATING OFFICER | SSale | −5.00K | $14.69 | −$73.5K | −14.0%30.6K after | |
| Jun 11, 2024 (view filing) | Jun 10 | 1 day | Ber GerardDirector | SSale | −722 | $12.00 | −$8.66K | −31.0%1.61K after | |
| Jun 11, 2024 (view filing) | Jun 10-11 | 1 day | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −70.0K | $12.02 | −$841.0K | −30.1%162.7K after | 2 lots |
| May 31, 2024 (view filing) | May 30-31 | 1 day | Kruse BoEVP, CFO, SECRY & TREAS. | SSale | −60.0K | $12.05 | −$723.1K | −22.2%210.9K after | 2 lots |
| May 23, 2024 (view filing) | May 21-23 | 2 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −32.4K | $12.23 | −$395.6K | −12.2%232.7K after | 2 lots |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Rajah VigneshSVP & CHIEF MEDICAL OFFICER | SSale | −1.71K | $16.53 | −$28.3K | −4.8%33.9K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in Y-mAbs Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 4,236,346 | $19.1M | 0.82% | 00.0% | Unchanged |
| Acorn Capital Advisors, LLC | 3,418,995 | $15.4M | 10.09% | +183,608+5.7% | Added |
| BlackRock, Inc. | 2,748,077 | $12.4M | 0.00% | −153,948−5.3% | Reduced |
| Caligan Partners LP | 2,342,609 | $10.6M | 2.05% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 2,194,278 | $9.90M | 0.67% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,943,285 | $8.76M | 0.00% | −3,224−0.2% | Reduced |
| Polar Capital Holdings Plc | 1,789,800 | $8.07M | 0.04% | −41,200−2.3% | Reduced |
| Geode Capital Management, LLC | 848,461 | $3.83M | 0.00% | −1,039−0.1% | Reduced |
| State Street Corp | 780,145 | $3.52M | 0.00% | −8,876−1.1% | Reduced |
| Boothbay Fund Management, LLC | 693,693 | $3.13M | 0.10% | 00.0% | Unchanged |
Holders of 5% or more of YMAB
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Y-mAbs Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Acorn Bioventures, L.P. | 13G/A | 6.20%2.80M shares | −0.80 ppfrom 7.00% | Aug 15, 20252 filings | Aug 20, 2025 | SEC |